Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

被引：67

作者：

Lu, Zhihao ^{[1
]}

Peng, Zhi ^{[1
]}

Liu, Chang ^{[1
]}

Wang, Zhenghang ^{[1
]}

Wang, Yakun ^{[1
]}

Jiao, Xi ^{[1
]}

Li, Jian ^{[1
]}

Shen, Lin ^{[1
]}

机构：

[1] Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Canc Hosp & Inst, 52 FuCheng Rd, Beijing 100142, Peoples R China

来源：

INNOVATION | 2020年 / 1卷 / 02期

关键词：

GASTROINTESTINAL CANCER; IMMUNE CHECKPOINT BLOCKADE; BIOMARKERS; PRECISION IMMUNOTHERAPY; GASTROESOPHAGEAL JUNCTION CANCER; ANTIGEN NANOVACCINE PVAC; T-CELL RECOGNITION; METASTATIC MELANOMA; CLINICAL-RESPONSE; CTLA-4; BLOCKADE; OPEN-LABEL; IPILIMUMAB TREATMENT; SOLID TUMORS; DOUBLE-BLIND;

D O I：

10.1016/j.xinn.2020.100041

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.

引用

页数：11